LOGIN  |  REGISTER
Terns Pharmaceuticals

List of Pharmaceutical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 755.39
-0.89 -0.12
1.79M
896.46M
US$ 677.180B
US$ 178.06
-0.44 -0.25
3.50M
2.41B
US$ 429.120B
US$ 218.34
-1.88 -0.85
3.11M
1.77B
US$ 386.460B
US$ 79.56
-1.54 -1.90
5.13M
3.10B
US$ 246.640B
US$ 124.12
-3.58 -2.80
1.75M
1.94B
US$ 240.790B
US$ 41.35
-0.72 -1.71
207,012
5.52B
US$ 228.250B
US$ 82.81
-2.34 -2.75
7.84M
2.50B
US$ 207.020B
US$ 54.87
0.57 1.05
9.78M
3.37B
US$ 184.910B
US$ 276.39
-6.34 -2.24
1.98M
538.36M
US$ 148.800B
US$ 114.55
-3.31 -2.81
6.52M
1.24B
US$ 142.040B
US$ 23.87
-0.99 -3.98
74.19M
5.69B
US$ 135.820B
US$ 47.03
-0.62 -1.30
2.95M
2.44B
US$ 114.750B
US$ 46.20
-1.34 -2.82
9.97M
2.04B
US$ 94.250B
US$ 40.83
-0.65 -1.57
4.46M
2.01B
US$ 82.070B
US$ 148.20
-2.41 -1.60
2.68M
443.18M
US$ 65.680B
US$ 15.10
-0.24 -1.56
2.66M
3.16B
US$ 47.720B
US$ 8.24
-0.21 -2.49
164,947
3.93B
US$ 32.380B
US$ 19.93
0.04 0.20
8.53M
1.15B
US$ 22.920B
US$ 144.86
-3.98 -2.67
2.01M
146.62M
US$ 21.240B
US$ 11.44
-0.04 -0.35
19,840
1.79B
US$ 20.480B
US$ 14.66
-0.07 -0.48
856,784
832.40M
US$ 12.200B
US$ 9.96
-0.21 -2.06
11.96M
1.17B
US$ 11.650B
US$ 34.96
0.00 0.00
0
330.76M
US$ 11.560B
US$ 63.48
0.00 0.00
0
181.51M
US$ 11.520B
US$ 18.53
-0.25 -1.33
4.37M
496.81M
US$ 9.210B
US$ 14.82
1.37 10.19
481,140
494.49M
US$ 7.330B
US$ 61.09
0.13 0.21
1.90M
79.44M
US$ 4.850B
US$ 26.28
0.92 3.63
409,360
166.19M
US$ 4.370B
US$ 17.93
1.56 9.53
112,404
171.86M
US$ 3.080B
US$ 9.21
-0.11 -1.18
181,359
334.72M
US$ 3.080B
US$ 22.27
-0.28 -1.24
1.05M
137.58M
US$ 3.060B
US$ 23.21
-0.67 -2.81
1.86M
124.77M
US$ 2.900B
US$ 10.65
-0.01 -0.09
2.10M
259.97M
US$ 2.770B
US$ 7.26
0.00 0.00
2.98M
369.79M
US$ 2.680B
US$ 9.88
-0.16 -1.59
429,546
258.22M
US$ 2.550B
US$ 45.46
-1.21 -2.59
443,606
56.07M
US$ 2.550B
US$ 97.71
-1.02 -1.03
179,785
21.69M
US$ 2.120B
US$ 37.10
0.09 0.24
414,487
43.47M
US$ 1.610B
US$ 15.40
-0.46 -2.90
1.32M
97.10M
US$ 1.500B
US$ 39.42
-0.03 -0.08
485,303
37.00M
US$ 1.460B
US$ 28.06
-0.62 -2.16
277,563
46.50M
US$ 1.300B
US$ 27.12
0.09 0.33
610,662
44.93M
US$ 1.220B
US$ 37.32
-1.75 -4.48
422,054
31.50M
US$ 1.180B
US$ 30.98
0.00 0.00
0
29.67M
US$ 919.180M
US$ 15.01
-0.31 -2.02
336,021
58.49M
US$ 877.930M
US$ 39.62
-1.55 -3.76
249,364
20.37M
US$ 807.060M
US$ 0.70
0.01 1.57
893,354
1.07B
US$ 747.930M
C$ 6.34
-0.09 -1.40
61,707
99.65M
C$ 631.780M
US$ 4.93
-0.11 -2.18
360,869
126.86M
US$ 625.420M
US$ 7.19
-0.32 -4.26
728,955
64.69M
US$ 465.120M
US$ 8.14
-0.09 -1.09
607,723
53.35M
US$ 434.270M
C$ 16.40
0.18 1.11
20,863
25.39M
C$ 416.400M
US$ 7.02
0.00 0.00
28,152
57.50M
US$ 403.650M
US$ 7.52
-0.25 -3.22
147,971
37.41M
US$ 281.320M
US$ 5.80
-0.09 -1.53
1.64M
47.42M
US$ 275.040M
US$ 6.09
0.03 0.50
114,714
45.03M
US$ 274.230M
US$ 4.45
-0.02 -0.45
225,356
53.52M
US$ 238.160M
US$ 2.02
0.30 17.44
437,984
116.03M
US$ 234.380M
US$ 1.31
0.07 5.65
868,713
162.43M
US$ 212.780M
C$ 5.65
-0.05 -0.88
7,314
31.39M
C$ 177.350M
US$ 3.30
0.02 0.61
767,066
45.98M
US$ 151.730M
US$ 7.11
-0.22 -3.00
142,474
20.31M
US$ 144.400M
C$ 11.82
0.00 0.00
1,050
11.26M
C$ 133.090M
US$ 1.01
0.00 0.00
0
112.82M
US$ 113.950M
C$ 3.04
-0.06 -1.94
26,510
32.26M
C$ 98.070M
US$ 9.60
0.00 0.00
0
10.13M
US$ 97.250M
US$ 1.07
0.00 0.00
826,669
83.73M
US$ 89.590M
US$ 0.09
-0.02 -21.53
6.53M
979.95M
US$ 88.200M
US$ 1.91
0.00 0.00
0
31.05M
US$ 59.310M
US$ 1.62
-0.07 -4.14
1.45M
34.43M
US$ 55.780M
US$ 1.52
-0.04 -2.56
122,487
34.83M
US$ 52.940M
US$ 3.44
0.01 0.29
33,691
14.96M
US$ 51.460M
US$ 3.45
-0.11 -3.09
178,376
14.65M
US$ 50.540M
US$ 0.54
0.009 1.70
44.38M
93.70M
US$ 50.500M
US$ 1.12
-0.06 -5.08
777,720
41.92M
US$ 46.950M
US$ 3.21
0.01 0.31
1,400
12.96M
US$ 41.600M
US$ 0.94
0.10 12.10
2.61M
30.21M
US$ 28.280M
US$ 1.43
-0.23 -13.86
1.52M
19.07M
US$ 27.270M
C$ 0.16
-0.005 -3.12
166,040
168.26M
C$ 26.080M
C$ 0.26
-0.005 -1.89
151,808
96.64M
C$ 25.130M
US$ 0.72
0.00 0.00
0
32.74M
US$ 23.590M
US$ 0.93
-0.07 -6.62
2.03M
20.52M
US$ 19.080M
US$ 0.94
0.05 5.09
164,159
19.36M
US$ 18.260M
US$ 0.43
-0.08 -15.74
8.76M
41.54M
US$ 18.030M
US$ 1.11
-0.01 -0.89
10,950
11.57M
US$ 12.840M
US$ 0.48
-0.03 -5.40
349,344
26.55M
US$ 12.610M
C$ 1.00
-0.12 -10.71
15,500
10.44M
C$ 10.440M
US$ 3.47
-0.01 -0.29
15,370
2.86M
US$ 9.920M
US$ 1.52
0.00 0.00
0
6.18M
US$ 9.390M
US$ 0.86
0.03 3.24
34,884
10.67M
US$ 9.180M
C$ 0.05
0.00 0.00
1,000
193.20M
C$ 8.690M
C$ 0.46
0.00 0.00
0
18.87M
C$ 8.590M
US$ 5.17
-0.01 -0.19
19,854
1.56M
US$ 8.070M
US$ 4.47
-0.08 -1.76
36,871
1.64M
US$ 7.330M
US$ 1.50
0.02 1.22
35,419
4.56M
US$ 6.830M
US$ 1.82
-0.07 -3.86
35,210
3.26M
US$ 5.920M
C$ 0.05
0.00 0.00
0
98.66M
C$ 4.440M
US$ 3.25
0.00 0.00
0
1.35M
US$ 4.390M
US$ 3.56
0.08 2.30
114,016
1.07M
US$ 3.810M
US$ 1.42
-0.02 -1.39
120,722
2.01M
US$ 2.850M
US$ 3.99
-0.09 -2.21
12,346
563,338
US$ 2.250M
US$ 0.03
0.00 0.00
541,802
42.37M
US$ 1.100M
C$ 0.005
0.00 0.00
0
132.63M
C$ 663K
US$ 0.00
0.00 0.00
0
13.96M
US$ -
US$ 0.00
0.00 0.00
0
64.47M
US$ -

Latest Pharmaceutical Stock News


Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J. / Sep 12, 2025 / Business Wire / Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats. Portela Will Be First Long-Acting Anti-NGF mAb Therapy for Cats,... Read more


Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”),... Read more


MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its... Read more


Bausch Health Completes Acquisition of DURECT, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire... Read more



Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000...

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Sky Pharm SA, signed a distribution agreement (the “Agreement”) with Scientific Pharmacy LLC (“Scientific Pharmacy”) for its Sky Premium Life food supplement products in Oman. Scientific Pharmacy, the retail and wholesale... Read more


Merck: CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

Results from the Phase 3 STRIDE-13 trial presented at the 6th ESCMID Conference on Vaccines Merck to share STRIDE-13 results with global regulatory authorities RAHWAY, N.J. / Sep 11, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) at the 6th European Society of Clinical Microbiology and Infectious... Read more


Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda’s Next CEO CAMBRIDGE, Mass. / Sep 11, 2025 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda’s U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the... Read more


Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction... Read more


Novo Nordisk to streamline operations and reinvest for growth

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients Intention to reduce ~9,000 roles globally with the expectation to deliver DKK 8bn of annualised savings by the end of 2026 One-off restructuring costs of DKK 8bn leading to an updated full-year 2025 operating profit growth outlook of 4–10% at CER Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today... Read more



Zomedica and UXR Announce Expanded Distribution Agreement in Canada

Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, announced today that it has expanded its distribution agreement with UXR Inc., a leading Canadian animal health company focused on supporting the needs... Read more


Lobe Sciences and Cynaptec Pharmaceuticals to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025

VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming Clusterbusters 20th Annual U.S. Patient Conference taking place September 11-14, 2025, in Grapevine, Texas (near Dallas/Ft. Worth). This conference is... Read more


Telix Pharmaceuticals Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study1) is the first regi... Read more


Johnson & Johnson: U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction1 Potential practice-changing treatment for certain patients with BCG-unresponsive non-muscle invasive bladder cancer who have limited options before possible bladder removal RARITAN, N.J., Sept. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today... Read more


Teva Pharmaceutical’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression. Emrusolmin is a small molecule that targets the alpha synuclein protein, which is... Read more


Eli Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines New offering expands Lilly Catalyze360's support for early-stage drug development INDIANAPOLIS, Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's... Read more


Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors

VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE) (OTCQB:LOBEF) (FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in... Read more


Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 Ascend Long-Term Extension Study in Adults with Moderate to Severe Atopic Dermatitis

THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate... Read more


Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

NEW BRUNSWICK, N.J. / Sep 08, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. “We are pleased to welcome John to our Company’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is a proven leader of a large multinational organization... Read more


Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has commenced a private offering (the “Offering”) of $250.0 million aggregate principal amount of senior unsecured notes due 2030... Read more


Eli Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine plus rituximab, indicating one of the most compelling effect sizes ever observed for a single agent BTK inhibitor in a front-line CLL study  BRUIN CLL-313 is the third positive Phase 3 study from the pirtobrutinib development program in CLL Results from BRUIN CLL-313... Read more


Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula First LP.8.1 sublineage clinical findings reinforce pre-clinical data supporting recent FDA approval of 2025-2026 Formula of Pfizer-BioNTech COVID-19 Vaccine Companies have submitted these data to the FDA NEW YORK & MAINZ, Germany... Read more


Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies SINGAPORE & OSAKA, Japan... Read more


Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient... Read more


Optimi Health Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common shares to be sold... Read more


Merck: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway BASKING RIDGE, N.J. & RAHWAY, N.J. / Sep 07, 2025 / Business Wire / Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These... Read more


AstraZeneca: TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced...

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del. / Sep 07, 2025 / Business Wire / Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy... Read more


Johnson & Johnson: Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated...

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RARITAN, N.J., Sept. 7, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced The New England Journal of Medicine (NEJM) published results from the Phase 3 MARIPOSA study, which showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrated... Read more


Johnson & Johnson: RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) significantly reduces the development of epidermal growth factor receptor (EGFR)-... Read more


Takeda: U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.... Read more


Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

17 abstracts accepted, including one oral presentation Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines... Read more


Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the reduction... Read more


Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The VENTANA HER2 (4B5) test is also now approved to help identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA. Roche continues to break ground as the leader in breast cancer... Read more


New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end Over 60% of people with a difficult-to-treat form of wet AMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed Vabysmo was well tolerated with a consistent long-term safety profile in wet AMD in both studies SOUTH SAN... Read more


HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (“WCLC”) taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology (“CSCO”) Annual Meeting 2025, taking place... Read more


Amgen To Present At The Morgan Stanley 23rd Annual Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously... Read more



Semnur Pharmaceuticals, a Majority-Owned Subsidiary of Scilex, and Denali Capital Acquisition Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination

PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the shareholders of Denali... Read more


Scynexis Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistance Additional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus species Company anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)... Read more


Eli Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer INDIANAPOLIS, Sept. 4, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination... Read more


Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma

Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia  Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 with pivotal PK trial planned for second half 2026  XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales&n... Read more


Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value FOSTER CITY, Calif. / Sep 03, 2025 / Business Wire / Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy... Read more


AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma...

Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first full dose of epcoritamab monotherapy, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with relapse... Read more



Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression

Export of 1,000 natural psilocybin capsules for prescription use under Australia's Authorised Prescriber Scheme follows the Company's successful launch of MDMA sales in 2024 Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia,... Read more


Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate currently in IND-enabling studies Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity; Argo is also eligible to receive option payment, development, sales milestones and royalties... Read more


Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio

Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions ANN ARBOR, MI / ACCESS Newswire / September 3, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a new distribution partnership in the United... Read more



 

  
  &